Failure-mode evidence depth
Coverage meters, not risk scores. Open the linked section to read direction.Stack
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
How stable is the peptide in biological matrices or protease systems?
What safety, toxicity, or tolerability evidence is attached?
Not availablePolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
3 Ro5 violations · MW 1,270.29 Da
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | Observation Not absorbed orally | Reported | PepTherDia curated product PK field | Route: ORAL · 75 · Micafungin · exact product name match · exact or normalized match | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 219700 ng*h/mL | Comparable | AUC ( 0 to 24 hrs) in healthy human plasma at 150 mg, iv TID · human · plasma | Route: iv · area under curve · AUC· AUC ( 0 to 24 hrs) in healthy human plasma at 150 mg, iv TID · Ex... | Open |
| 2 | 79200 ng*h/mL | Comparable | AUC (0 to 24 hrs) in lung transplant recipient invasive aspergillosis patient plasma at 150 mg, iv administered as single dose · human · plasma | Route: iv · area under curve · AUC· AUC (0 to 24 hrs) in lung transplant recipient invasive aspergill... | Open |
| 3 | 219700 ng*h/mL | Comparable | AUC (0 to 24 hrs) in lung transplant recipient invasive aspergillosis patient plasma at 150 mg, iv QD for 3 consecutive days measured post last dose · human · plasma | Route: iv · area under curve · AUC· AUC (0 to 24 hrs) in lung transplant recipient invasive aspergill... | Open |
| 4 | 126000 ng*h/mL | Comparable | AUC in healthy human at 100 mg/day · human | area under curve · AUC· AUC in healthy human at 100 mg/day · Exact ChEMBL pref name MICAF... | Open |
| 5 | 55 μg*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table auc ss mean · Table 8. Sum... | Open |
| 6 | 109 μg*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table auc ss mean · Table 8. Sum... | Open |
| 7 | 164 μg*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table auc ss mean · Table 8. Sum... | Open |
| 8 | 67 μg*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table auc ss mean · Table 8. Sum... | Open |
| 9 | 134 μg*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table auc ss mean · Table 8. Sum... | Open |
| 10 | 176 μg*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table auc ss mean · Table 8. Sum... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 15035.94 nM | Comparable | Cmax in healthy human plasma at 150 mg, iv TID · human · plasma | Route: iv · max concentration · Cmax· Cmax in healthy human plasma at 150 mg, iv TID · Exact ChEMBL p... | Open |
| 2 | 3881 nM | Comparable | Cmax in lung transplant recipient invasive aspergillosis patient plasma at 150 mg, iv QD for 4 consecutive days by HPLC · human · plasma | Route: iv · max concentration · Cmax· Cmax in lung transplant recipient invasive aspergillosis patien... | Open |
| 3 | 7.1 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table cmax ss mean · Table 8. Su... | Open |
| 4 | 14.2 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table cmax ss mean · Table 8. Su... | Open |
| 5 | 21.3 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table cmax ss mean · Table 8. Su... | Open |
| 6 | 8.7 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table cmax ss mean · Table 8. Su... | Open |
| 7 | 17.5 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table cmax ss mean · Table 8. Su... | Open |
| 8 | 23 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table cmax ss mean · Table 8. Su... | Open |
| 9 | 8 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin table adult cmax hiv ec day1 100mg · Pharm... | Open |
| 10 | 11.6 μg/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin table adult cmax hiv ec day1 150mg · Pharm... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 4 hr 14400 seconds | Comparable | Tmax in lung transplant recipient invasive aspergillosis patient plasma at 150 mg, iv QD for 4 consecutive days by HPLC · human · plasma | Route: iv · time to max concentration · Tmax· Tmax in lung transplant recipient invasive aspergillosi... | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.39 L/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin distribution terminal phase mean · Distrib... | Open |
| 2 | 0.52 L/kg | Comparable | Volume of distribution at steady state in analbuminemic Nagase rat plasma at 1 mg/kg, iv administered as single dose by high-performance liquid chromatography · rat · plasma | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in analbuminemic Na... | Open |
| 3 | 0.21 L/kg | Comparable | Volume of distribution at steady state in human after iv administration · human | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in human after iv a... | Open |
| 4 | 0.54 L/kg | Comparable | Volume of distribution at steady state in Sprague-Dawley rat plasma at 1 mg/kg, iv administered as single dose by high-performance liquid chromatography · rat · plasma | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in Sprague-Dawley r... | Open |
| 5 | 15 L | Comparable | Volume of distribution in healthy human plasma at 150 mg, iv TID · human · plasma | Route: iv · volume of distribution · Vd· Volume of distribution in healthy human plasma at 150 mg, iv... | Open |
| 6 | 10.43 L | Comparable | Volume of distribution in iv dosed adult human by HPLC · human | Route: iv · volume of distribution · Vd· Volume of distribution in iv dosed adult human by HPLC · Exa... | Open |
| 7 | 10.3 L | Comparable | Volume of distribution in iv dosed human infant by HPLC · human | Route: iv · volume of distribution · Vd· Volume of distribution in iv dosed human infant by HPLC · Ex... | Open |
| 8 | 17.62 L | Comparable | Volume of distribution in lung transplant recipient invasive aspergillosis patient at 150 mg, iv QD for 4 consecutive days by HPLC · human | Route: iv · volume of distribution · Vd· Volume of distribution in lung transplant recipient invasive... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 99 % | Comparable | PepTherDia curated product PK field · plasma protein | Route: IV · 75 · Micafungin · exact product name match · exact or normalized match | Open |
| 2 | 99 % | Comparable | Plasma protein binding in healthy human · human · plasma | plasma protein binding · PPB· Plasma protein binding in healthy human · Exact ChEMBL pref... | Open |
| 3 | 99.8 % | Comparable | Protein binding in human serum · human · serum | plasma protein binding · PPB· Protein binding in human serum · Exact ChEMBL pref name MIC... | Open |
| 4 | > 99 % | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Micafungin· 12.3 Pharmacokinetics · micafungin protein binding greater than · Micafungin... | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Clearance and half-life evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.7 L/h | Comparable | Clearance at steady state in healthy human plasma at 150 mg, iv TID · human · plasma | Route: iv · clearance · CL· Clearance at steady state in healthy human plasma at 150 mg, iv TID · Exa... | Open |
| 2 | 0.17 mL/min/kg | Comparable | Clearance in human after iv administration · human | Route: iv · clearance · CL· Clearance in human after iv administration · Exact ChEMBL pref name MICAF... | Open |
| 3 | 1.309 L/h | Comparable | Clearance in lung transplant recipient invasive aspergillosis patient at 150 mg, iv QD for 4 consecutive days by HPLC · human | Route: iv · clearance · CL· Clearance in lung transplant recipient invasive aspergillosis patient at... | Open |
| 4 | 0.328 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table clearance mean · Table 8.... | Open |
| 5 | 0.241 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin pediatric table clearance mean · Table 8.... | Open |
| 6 | 0.327 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin table adult clearance hiv ec day1 100mg ·... | Open |
| 7 | 0.34 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin table adult clearance hiv ec day1 150mg ·... | Open |
| 8 | 0.321 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin table adult clearance hiv ec day1 50mg · P... | Open |
| 9 | 0.301 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin table adult clearance hiv ec day14 21 100m... | Open |
| 10 | 0.297 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Micafungin· 12.3 Pharmacokinetics · micafungin table adult clearance hiv ec day14 21 150m... | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
The identity reference does not expose a sequence string.
No reported sequence notation is available in the current identity references.
No sequence representation
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference link | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Plasma Protein Binding +1 more | No reported alias | 0 identity 60 evidence |
PubMed 20308367 | DistributionExposurePersistence Area Under Curve, Clearance, Volume Of Distribution | No reported alias | 0 identity 7 evidence |
PubMed 20439610 | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Time To Max Concentration +1 more | No reported alias | 0 identity 6 evidence |
PubMed 19114675 | DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Plasma Protein Binding +1 more | No reported alias | 0 identity 5 evidence |
Reference link | DistributionExposure Bioavailability, Plasma Protein Binding | No reported alias | 1 identity 2 evidence |
PubMed 18591270 | DistributionPersistence Clearance, Volume Of Distribution | No reported alias | 0 identity 3 evidence |
PubMed 18426954 | DistributionPersistence Clearance, Volume Of Distribution | No reported alias | 0 identity 2 evidence |
PubMed 18625768 | Exposure Area Under Curve | No reported alias | 0 identity 1 evidence |
PubMed 19687246 | Distribution Plasma Protein Binding | No reported alias | 0 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0019880' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.